Skip to main content
Premium Trial:

Request an Annual Quote

Definiens, Cernostics Team on Multiplex Cancer Tests

By a GenomeWeb Staff Reporter

NEW YORK (GenomeWeb News) – Definiens and Cernostics today announced that they will collaborate on the development of multiplex molecular diagnostics tests for a variety of cancers.

Danville, Pa.-based Cernostics will use Definiens' Tissue Studio digital pathology technology to develop the tests. The Definiens technology enables pathologists to analyze cancers on the cellular and sub-cellular level, the firms said.

"The collaboration with Definiens will enable Cernostics to accelerate development of its pipeline of systems biology-based diagnostic, prognostic and predictive tests," Cernostics CEO Michael Hoerres said in a statement.

Terms of the alliance were not disclosed.

Last year, Cernostics teamed up with Geisinger Health Systems to develop diagnostics for detecting cellular and molecular differences in patient tissue samples.

The Scan

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.

Team Presents Cattle Genotype-Tissue Expression Atlas

Using RNA sequences representing thousands of cattle samples, researchers looked at relationships between cattle genotype and tissue expression in Nature Genetics.

Researchers Map Recombination in Khoe-San Population

With whole-genome sequences for dozens of individuals from the Nama population, researchers saw in Genome Biology fine-scale recombination patterns that clustered outside of other populations.

Myotonic Dystrophy Repeat Detected in Family Genome Sequencing Analysis

While sequencing individuals from a multi-generation family, researchers identified a myotonic dystrophy type 2-related short tandem repeat in the European Journal of Human Genetics.